• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Sotera Health Chairman and CEO Presents at 43rd Annual J.P. Morgan Healthcare Conference

    1/14/25 7:30:09 AM ET
    $SHC
    Misc Health and Biotechnology Services
    Health Care
    Get the next $SHC alert in real time by email

    CLEVELAND, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is presenting today at the 43rd Annual J.P. Morgan Healthcare Conference. During the presentation, Chairman and CEO Michael B. Petras, Jr. will be providing an update on Sotera Health's business.

    "I am pleased to announce that Sotera Health delivered another year of top-line growth in 2024," said Mr. Petras. "We expect full-year revenues will be approximately $1.1 billion, representing growth of nearly 5% versus 2023 and more than 5% growth on a constant currency basis. The growth we experienced in 2024 is a testament to the resiliency of our business model, which allows us to serve our customers with excellence in all types of market environments. We look forward to reporting our full 2024 financial results and 2025 outlook on February 27, 2025."

    Mr. Petras, Jon Lyons, Senior Vice-President and CFO, and Jason Peterson, Vice President, Investor Relations and Treasurer, are participating in meetings with investors during the conference. A live webcast of Mr. Petras' presentation and accompanying materials may be accessed via the Investor Relations section of the Company's website at Presentation & Events | Sotera Health. A replay of the webcast will be archived on the Company's website.

    Cautionary Note Regarding Forward-Looking Statements

    Unless expressly indicated or the context requires otherwise, the terms "Sotera Health," "Company," "we," "us," and "our" in this document refer to Sotera Health Company, a Delaware corporation, and, where appropriate, its subsidiaries on a consolidated basis. This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and reflect management's expectations about future events and the Company's operating plans and performance and speak only as of the date hereof. Forward-looking statements present our current forecasts and estimates of future events. These statements do not strictly relate to historical or current results and can be identified by words such as "anticipate," "appear," "assume," "believe," "estimate," "expect," "forecast," "intend," "likely," "may," "plan," "project," "seek," "should," "strategy," "will" and other terms of similar meaning or import in connection with any discussion of future operating, financial or other performance. These forward-looking statements are subject to risks, uncertainties and other factors and actual results may differ materially from those results projected in the statements. These forward-looking statements are subject to various risks, uncertainties and assumptions relating to our operations, financial results, financial condition, business, prospects, growth strategy and liquidity. These risks and uncertainties include, but are not limited to, a disruption in the availability or supply of, or increases in the price of, ethylene oxide ("EO"), Cobalt-60 ("Co-60") or our other direct materials, services and supplies, including as a result of geopolitical instability and/or sanctions against Russia by the United States, Canada, United Kingdom and/or the European Union; fluctuations in foreign currency exchange rates; changes in environmental, health and safety regulations or preferences, and general economic, social and business conditions; health and safety risks associated with the use, storage, transportation and disposal of potentially hazardous materials such as EO and Co-60; the impact and outcome of current and future legal proceedings and liability claims, including litigation related to the use, emissions and releases of EO from our facilities in California, Georgia, Illinois and New Mexico and the possibility that additional claims will be made in the future relating to these or other facilities; allegations of our failure to properly perform services and potential product liability claims, recalls, penalties and reputational harm; compliance with the extensive regulatory requirements to which we are subject, the related costs, and any failures to receive or maintain, or delays in receiving, required clearances or approvals; adverse changes in industry trends; competition we face; market changes, including inflationary trends, that impact our long-term supply contracts with variable price clauses and increase our cost of revenues; business continuity hazards, including supply chain disruptions and other risks associated with our operations; the risks of doing business internationally, including global and regional economic and political instability and compliance with numerous laws and sometimes inconsistent laws and regulations in multiple jurisdictions; our ability to increase capacity at existing facilities, build new facilities in a timely and cost-effective manner and renew leases for our leased facilities; our ability to attract and retain qualified employees; severe health events or environmental events; cybersecurity breaches, unauthorized data disclosures, and our dependence on information technology systems; an inability to pursue strategic transactions, find suitable acquisition targets, or integrate strategic acquisitions into our business successfully; our ability to maintain effective internal control over financial reporting; our reliance on intellectual property to maintain our competitive position and the risk of claims from third parties that we have infringed or misappropriated, or are infringing or misappropriating, their intellectual property rights; our ability to comply with rapidly evolving data privacy and security laws and regulations in various jurisdictions and any ineffective compliance efforts with such laws and regulations; our ability to maintain profitability in the future; impairment charges on our goodwill and other intangible assets with indefinite lives, as well as other long-lived assets and intangible assets with definite lives; the effects of unionization efforts and labor regulations in countries in which we operate; adverse changes to our tax positions in U.S. or non-U.S. jurisdictions or the interpretation and application of recent U.S. tax legislation or other changes in U.S. or non-U.S. taxation of our operations; and our significant leverage and how this significant leverage could adversely affect our ability to raise additional capital, limit our ability to react to challenges confronting our Company or broader changes in our industry or the economy, limit our flexibility in operating our business through restrictions contained in our debt agreements and/or prevent us from meeting our obligations under our existing and future indebtedness. For additional discussion of these risks and uncertainties, please refer to the Company's filings with the SEC, such as its Annual Report on Form 10-K and quarterly reports. We do not undertake any obligation to publicly update or revise these forward-looking statements, except as otherwise required by law.

    The Company's financial statement closing procedures for the three months and year ended December 31, 2024 are not yet complete and, as a result, the financial information above reflects the Company's preliminary estimates with respect to such results based on information currently available to management. The Company's actual financial results as of and for the three months and year ended December 31, 2024 may vary materially from these preliminary estimates due to the completion of our financial statement closing procedures, final adjustments and other developments arising between now and the time that our financial results for the three months and year ended December 31, 2024 are released. Estimates of financial results are inherently uncertain and we undertake no obligation to update this information.

    About Sotera Health

    Sotera Health Company is a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry. Sotera Health goes to market through three businesses – Sterigenics®, Nordion® and Nelson Labs®. Sotera Health is committed to its mission, Safeguarding Global Health®.

    Updates can be found from time to time on recent developments in matters relevant to investors on the Investor Relations section of the Company's website at Investor Relations | Sotera Health. For developments related to Ethylene Oxide, updates can be found at Ethylene Oxide | Sotera Health.

    Contacts:

    Jason Peterson

    Vice President, Investor Relations & Treasurer

    [email protected]

    Kristin Gibbs

    Chief Marketing Officer

    [email protected]

    Source: Sotera Health Company



    Primary Logo

    Get the next $SHC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SHC

    DatePrice TargetRatingAnalyst
    5/5/2025$17.00Neutral → Buy
    Goldman
    12/6/2024$14.00Neutral
    Goldman
    5/21/2024$13.00Neutral
    Piper Sandler
    4/3/2024$18.00 → $16.00Neutral → Buy
    Citigroup
    3/25/2024$15.00 → $15.50Hold → Buy
    Jefferies
    2/6/2024Sector Weight
    KeyBanc Capital Markets
    6/26/2023$24.00Sector Weight → Overweight
    KeyBanc Capital Markets
    1/23/2023$6.00 → $18.00Underweight → Neutral
    JP Morgan
    More analyst ratings

    $SHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sotera Health upgraded by Goldman with a new price target

      Goldman upgraded Sotera Health from Neutral to Buy and set a new price target of $17.00

      5/5/25 8:27:32 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Goldman initiated coverage on Sotera Health with a new price target

      Goldman initiated coverage of Sotera Health with a rating of Neutral and set a new price target of $14.00

      12/6/24 8:14:45 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Piper Sandler initiated coverage on Sotera Health with a new price target

      Piper Sandler initiated coverage of Sotera Health with a rating of Neutral and set a new price target of $13.00

      5/21/24 7:45:20 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care

    $SHC
    Financials

    Live finance-specific insights

    See more
    • Sotera Health Reports First-Quarter 2025 Results

      Q1 2025 net revenues increased 2.6% to $255 million, compared to Q1 2024, or 4.4% on a constant currency basisQ1 2025 net loss of $13 million or $0.05 per diluted share, compared to net income of $6 million or $0.02 per diluted share in Q1 2024Q1 2025 Adjusted EBITDA(1) increased 8.8% to $122 million, compared to Q1 2024, or 11.2% on a constant currency basisQ1 2025 Adjusted EPS(1) of $0.14, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.13 in Q1 2024Company reaffirms full-year 2025 outlook of 4.0% - 6.0% net revenues growth and 4.5% - 6.5% Adjusted EBITDA growth, both on a constant currency basis CLEVELAND, May 01, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("

      5/1/25 7:38:53 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Announces First-Quarter 2025 Earnings Release Date

      CLEVELAND, April 17, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the first-quarter ended March 31, 2025 before the market opens on Thursday, May 1, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company's financial results and operating highlights. To participate in the live call, please dial 1-844-481-2916 (toll-free in the United States), or 1-412-317-0709 if dialing-in from other locations.

      4/17/25 5:16:45 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Reports Fourth-Quarter and Full-Year 2024 Results; Provides 2025 Outlook

      2024 net revenues increased 4.9% to $1.10 billion, compared to 2023; or 5.4% on a constant currency basis2024 net income of $44 million or $0.16 per diluted share, compared to 20232024 Adjusted EBITDA(1) increased 3.9% to $549 million, compared to 2023; or 4.6% on a constant currency basis2024 Adjusted EPS(1) of $0.70, a decrease of $0.02 per diluted share, compared to 2023Full-year 2025 outlook of 4.0% - 6.0% net revenues growth and 4.5% - 6.5% Adjusted EBITDA growth, both on a constant currency basis CLEVELAND, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("Sotera Health" or the "Company") (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization so

      2/27/25 7:00:37 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care

    $SHC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sotera Health Reports First-Quarter 2025 Results

      Q1 2025 net revenues increased 2.6% to $255 million, compared to Q1 2024, or 4.4% on a constant currency basisQ1 2025 net loss of $13 million or $0.05 per diluted share, compared to net income of $6 million or $0.02 per diluted share in Q1 2024Q1 2025 Adjusted EBITDA(1) increased 8.8% to $122 million, compared to Q1 2024, or 11.2% on a constant currency basisQ1 2025 Adjusted EPS(1) of $0.14, an increase of $0.01 per diluted share, compared to Adjusted EPS of $0.13 in Q1 2024Company reaffirms full-year 2025 outlook of 4.0% - 6.0% net revenues growth and 4.5% - 6.5% Adjusted EBITDA growth, both on a constant currency basis CLEVELAND, May 01, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company ("

      5/1/25 7:38:53 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Announces First-Quarter 2025 Earnings Release Date

      CLEVELAND, April 17, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced it will release its financial results for the first-quarter ended March 31, 2025 before the market opens on Thursday, May 1, 2025. Following the release, management will host a conference call at 9:00 a.m. Eastern Daylight Time to discuss the Company's financial results and operating highlights. To participate in the live call, please dial 1-844-481-2916 (toll-free in the United States), or 1-412-317-0709 if dialing-in from other locations.

      4/17/25 5:16:45 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Nelson Labs Launches Innovative Rapid Sterility Testing to Significantly Expedite Product Sterility Results

      SALT LAKE CITY, March 04, 2025 (GLOBE NEWSWIRE) -- Nelson Labs, a Sotera Health company and a global leader in microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries, now performs product-sterility testing through rapid microbiological methods (RMMs) at three laboratory sites located in the United States and Europe. Nelson Labs' testing solution is unique in that it supports a broad range of both medical devices and pharmaceutical products. This innovative approach broadens the scope of Rapid Sterility Testing—a field that has primarily focused on products with biological components or short shelf life—by providing a vers

      3/4/25 7:00:37 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care

    $SHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman & CEO Petras Michael B. Jr. covered exercise/tax liability with 100,849 shares and was granted 298,953 shares, increasing direct ownership by 30% to 868,603 units (SEC Form 4)

      4 - Sotera Health Co (0001822479) (Issuer)

      3/4/25 9:49:47 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • President of Sterigenics Rutz Michael P covered exercise/tax liability with 13,284 shares and was granted 48,579 shares, increasing direct ownership by 7% to 576,815 units (SEC Form 4)

      4 - Sotera Health Co (0001822479) (Issuer)

      3/4/25 8:38:48 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sr. Vice President, CFO Lyons Jonathan M. covered exercise/tax liability with 6,481 shares and was granted 97,159 shares, increasing direct ownership by 82% to 201,110 units (SEC Form 4)

      4 - Sotera Health Co (0001822479) (Issuer)

      3/4/25 8:36:07 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care

    $SHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sotera Health Company

      SC 13G/A - Sotera Health Co (0001822479) (Subject)

      11/14/24 4:51:55 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sotera Health Company

      SC 13G/A - Sotera Health Co (0001822479) (Subject)

      11/14/24 4:50:09 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sotera Health Company

      SC 13G/A - Sotera Health Co (0001822479) (Subject)

      11/12/24 5:53:58 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care

    $SHC
    Leadership Updates

    Live Leadership Updates

    See more
    • Sotera Health Company Appoints Vincent K. Petrella as Lead Independent Director

      CLEVELAND, Ohio, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is pleased to announce today the appointment of Vincent K. Petrella as Lead Independent Director, effective January 2, 2025. Mr. Petrella, who has served on Sotera Health Company's Board of Directors since 2020, brings a wealth of experience and a deep understanding of the Company's strategic vision and operations. In this newly appointed role, Mr. Petrella will serve as a key liaison among the Board, management and shareholders. Mr. Petrella has decades of

      1/6/25 4:30:38 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Appoints Christopher Simon to the Board of Directors

      CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previ

      8/1/24 7:00:02 AM ET
      $HAE
      $SHC
      Medical/Dental Instruments
      Health Care
      Misc Health and Biotechnology Services
    • Sotera Health Appoints Karen Flynn to Board of Directors

      CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal

      11/13/23 7:00:14 AM ET
      $CTLT
      $QTRX
      $SHC
      $WST
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $SHC
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Sotera Health Company

      DEFA14A - Sotera Health Co (0001822479) (Filer)

      5/2/25 4:05:40 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 10-Q filed by Sotera Health Company

      10-Q - Sotera Health Co (0001822479) (Filer)

      5/1/25 4:05:19 PM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care
    • Sotera Health Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Sotera Health Co (0001822479) (Filer)

      5/1/25 7:45:45 AM ET
      $SHC
      Misc Health and Biotechnology Services
      Health Care